Preoperative high levels of serum vascular endothelial growth factor are a prognostic marker for poor outcome after surgical treatment of renal cell carcinoma

Scandinavian Journal of Urology

Volumn 49, Issue 5, 2015, Pages 388-394

  Guebrandsdottir, Gigja ^a   Hjelle, Karin M ^a,b   Frugård, Jannicke ^a   Bostad, Leif ^b,c   Aarstad, Hans J ^a,b   Beisland, Christian ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c Department of Pathology ^*  (United States)

Author keywords

Diagnostics; prognosis; recurrence; renal cell carcinoma; VEGF

Indexed keywords

ALKALINE PHOSPHATASE; C REACTIVE PROTEIN; CREATININE; HEMOGLOBIN; VASCULOTROPIN; TUMOR MARKER; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; DISTANT METASTASIS; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; NEPHRON SPARING SURGERY; PREDICTIVE VALUE; PREOPERATIVE CARE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENCE FREE SURVIVAL; TREATMENT OUTCOME; TUMOR VOLUME; VERY ELDERLY; BLOOD; CARCINOMA, RENAL CELL; FOLLOW UP; KIDNEY NEOPLASMS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; TUMOR RECURRENCE;

ADULT; AGED; BIOMARKERS, TUMOR; CARCINOMA, RENAL CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEPHRECTOMY; PROGNOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84946725037     PISSN: 21681805     EISSN: 21681813     Source Type: Journal    
DOI: 10.3109/21681805.2015.1021833     Document Type: Article

References (28)

1. Jagdev SP, Gregory W, Vasudev NS, Harnden P, Sim S, Thompson D, et al. Improving the accuracy of pre-operative survival prediction in renal cell carcinoma with C-reactive protein. Br J Cancer 2010;103:1649-56.
2. Ljungberg B, Campbell SC, Cho HY, Jacqmin D, Lee JE, Weikert S, et al. The epidemiology of renal cell carcinoma. Eur Urol 2011;60:615-21.
3. Larsen IK. Cancer Registry of Norway. Cancer in Norway 2012-cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway; 2014.
4. Smastuen M, Johannesen T, Møller B, Bray F. Long-term cancer survival: patterns and trends in Norway 1965-2007. Oslo: Cancer Registry of Norway; 2008.
5. Finley DS, Pantuck AJ, Belldegrun AS. Tumor biology and prognostic factors in renal cell carcinoma. Oncologist 2011;16:4-13.
6. Ferrara N. Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 2009;29:789-91.
7. Grunewald FS, Prota AE, Giese A, Ballmer-Hofer K. Structure-function analysis of VEGF receptor activation and the role of coreceptors in angiogenic signaling. Biochim Biophys Acta 2010;1804:567-80.
8. Simons M. An inside view: VEGF receptor trafficking and signaling. Physiology (Bethesda) 2012;27:213-22.
9. Rioux-Leclercq N, Fergelot P, Zerrouki S, Leray E, Jouan F, Bellaud P, et al. Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: A prospective study of 50 cases. Hum Pathol 2007;38:1489-95.
10. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004;9:2-10.
11. Schips L, Dalpiaz O, Lipsky K, Langner C, Rehak P, Puerstner P, et al. Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group. Eur Urol 2007;51:168-74.
12. Welti J, Loges S, Dimmeler S, Carmeliet P. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest 2013;123:3190-200.
13. Dosquet C, Coudert MC, Lepage E, Cabane J, Richard F. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin Cancer Res 1997;3:2451-8.
14. George S, Bukowski RM. Biomarkers in clear cell renal cell carcinoma. Expert Rev Anticancer Ther 2007;7:1737-47.
15. Beisland C, Hjelle KM, Reisæter LAR, Bostad L. Observation should be considered as an alternative in management of renal masses in older and comorbid patients. Eur Urol 2009;55:1419-29.
16. Sun M, Bianchi M, Trinh Q-D, Hansen J, Abdollah F, Hanna N, et al. Comparison of partial vs radical nephrectomy with regard to other-cause mortality in T1 renal cell carcinoma among patients aged 75 years with multiple comorbidities. BJU Int 2013;111:67-73.
17. Greene FL, Sobin LH. A worldwide approach to the TNM staging system: collaborative efforts of the AJCC and UICC. J Surg Oncol 2009;99:269-72.
18. Fuhrman SA LL, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Pathol 1982;6:655-63.
19. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972;34:187-220.
20. Jacobsen JAN, Rasmuson T, Grankvist K, Ljungberg B. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 2000;163:343-7.
21. Fujita N, Okegawa T, Tambo M, Shishido T, Nutahara K, Higashihara E. [Predicting postoperative recurrence of renal cell carcinoma using serum vascular endothelial growth factor]. Nihon Hinyokika Gakkai Zasshi 2013;104:1-5.
22. Negrier S, Perol D, Menetrier-Caux C, Escudier B, Pallardy M, Ravaud A, et al. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6-from the Groupe Français d'Immunothe-rapie. J Clin Oncol 2004;22:2371-8.
23. Polimeno M, Napolitano M, Costantini S, Portella L, Esposito A, Capone F, et al. Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma. BJU Int 2013;112:686-96.
24. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. J Clin Oncol 2009;27:3312-18.
25. Kim JJ, Vaziri SAJ, Rini BI, Elson P, Garcia JA, Wirka R, et al. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer 2012;118:1946-54.
26. Sand KE, Hjelle KM, Rogde AJ, Gudbrandsdottir G, Bostad L, Beisland C. Incidentally detected renal cell carcinomas are highly associated with comorbidity and mortality unrelated to renal cell carcinoma. Scand J Urol 2013;47:462-71.
27. Gumundsson E, Hellborg H, Lundstam S, Erikson S, Ljungberg B. Metastatic potential in renal cell carcinomas €7 cm: Swedish Kidney Cancer Quality Register data. Eur Urol 2011;60:975-82.
28. Sciarra A, Cattarino S, Salciccia S, Alfarone A, Gentilucci A, Parente U, et al. The emerging role of targeted therapy in renal cell carcinoma (RCC): is it time for a neoadjuvant or an adjuvant approach? Crit Rev Oncol Hematol 2012;81:151-62.